Multisystem morbidity and mortality in cushing's syndrome: A cohort study

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 6, 2013, Pages 2277-2284

  Dekkers, Olaf M ^a   Horváth Puh́o, Erzsébet ^b   Jørgensen, Jens Otto L ^b   Cannegieter, Suzanne C ^a   Ehrenstein, Vera ^b   Vandenbroucke, Jan P ^a   Pereira, Alberto M ^a   Srøensen, Henrik Toft ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ADRENALECTOMY; ADULT; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; CUSHING SYNDROME; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FRACTURE; HEART FAILURE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PEPTIC ULCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ADULT; COHORT STUDIES; CUSHING SYNDROME; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; STROKE; VENOUS THROMBOEMBOLISM;

EID: 84878494420     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3582     Document Type: Article

References (32)

1. Lindholm J, Juul S, Jørgensen JO, et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86:117-123. (Pubitemid 32111743)
2. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994;40:479-484. (Pubitemid 24194645)
3. Pereira AM, van Aken MO, van Dulken H, et al. Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J Clin Endocrinol Metab. 2003;88:5858-5864. (Pubitemid 38033063)
4. Colao A, Petersenn S, Newell-Price J, et al. A12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366:914-924.
5. Feelders RA, Hofland LJ, de Herder WW. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology. 2010;1(92 suppl 1):111-115.
6. Flitsch J, Spitzner S, Lüdecke DK. Emotional disorders in patients with different types of pituitary adenomas and factors affecting the diagnostic process. Exp Clin Endocrinol Diabetes. 2000;108:480-485.
7. Van Zaane B, Nur E, Squizzato A, et al. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab. 2009;94:2743-2750.
8. Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87:4872-4878. (Pubitemid 35316318)
9. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf). 2004;61:768-777. (Pubitemid 40006799)
10. Minetto M, Reimondo G, Osella G, Ventura M, Angeli A, Terzolo M. Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome. Osteoporos Int. 2004;15:855-861. (Pubitemid 39506451)
11. da Mota F, Murray C, Ezzat S. Overt immune dysfunction after Cushing's syndrome remission: a consecutive case series and review of the literature. J Clin Endocrinol Metab. 2011;96:E1670-E1674.
12. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84:2664-2672. (Pubitemid 30641990)
13. Barahona M-J, Sucunza N, Resmini E, et al. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab. 2009;94:3365-3371.
14. Geer EB, Shen W, Strohmayer E, Post KD, Freda PU. Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab. 2012;97:1702-1711.
15. Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jørgensen JOL. Mortality in Cushing's syndrome: a systematic review and meta-analysis. Eur J Intern Med. 2012;23:278-282.
16. Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2007;92:976-981. (Pubitemid 46465672)
17. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011;96:632-642.
18. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39:30-33.
19. Frank L. Epidemiology. When an entire country is a cohort. Science. 2000;287:2398-2399. (Pubitemid 30185417)
20. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593-5602. (Pubitemid 38033020)
21. Pereira AM, Delgado V, Romijn JA, Smit JWA, Bax JJ, Feelders RA. Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome. Eur J Endocrinol. 2010;162:331-340.
22. De Leo M, Pivonello R, Auriemma RS, et al. Cardiovascular disease in Cushing's syndrome: heart versus vasculature. Neuroendocrinology. 2010;1(92 suppl 1):50 -54.
23. Stuijver DJF, van Zaane B, Feelders RA, et al. Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. J Clin Endocrinol Metab. 2011;96:3525-3532.
24. Bolland MJ, Holdaway IM, Berkeley JE, et al. Mortality and morbidity in Cushing's syndrome in New Zealand. Clin Endocrinol (Oxf). 2011;75:436-442.
25. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83.
26. Androulakis II, Kaltsas G, Piaditis G, Grossman AB. The clinical significance of adrenal incidentalomas. Eur J Clin Invest. 2011;41:552-560.
27. Swearingen B, Biller BM, Barker FG, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med. 1999;130:821-824. (Pubitemid 29231150)
28. Prevedello DM, Pouratian N, Sherman J, et al. Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J Neurosurg. 2008;109:751-759.
29. Dekkers OM, von Elm E, Algra A, Romijn JA, Vandenbroucke JP. Howto assess the external validity of therapeutic trials: a conceptual approach. Int J Epidemiol. 2010;39:89-94.
30. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492-499.
31. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-578. (Pubitemid 351232031)
32. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93:105-111. (Pubitemid 30098773)